Abstract
This review examines the impact of moderate to severe dry eye disease on daily life and medical-resource utilization. The results suggest that current treatment paradigms can lead to unacceptable costs in both quality of life and progressive use of healthcare resources. Evidence linking this disease to T-cell-mediated inflammatory processes lays the foundation for understanding the clinical benefits of topical cyclosporine, an immunomodulatory and anti- inflammatory agent.
Original language | English (US) |
---|---|
Pages (from-to) | 84-93 |
Number of pages | 10 |
Journal | Advances in Therapy |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - 2000 |
Externally published | Yes |
Keywords
- Cyclosporine
- Dry eye
- Inflammatory response